[HTML][HTML] Treatment resistance in psychiatry: state of the art and new directions

OD Howes, ME Thase, T Pillinger - Molecular psychiatry, 2022 - nature.com
Abstract Treatment resistance affects 20–60% of patients with psychiatric disorders; and is
associated with increased healthcare burden and costs up to ten-fold higher relative to …

The schizophrenia syndrome, circa 2024: What we know and how that informs its nature

R Tandon, H Nasrallah, S Akbarian… - Schizophrenia …, 2024 - Elsevier
With new data about different aspects of schizophrenia being continually generated, it
becomes necessary to periodically revisit exactly what we know. Along with a need to review …

A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia

CU Correll, O Agid, B Crespo-Facorro… - CNS drugs, 2022 - Springer
Abstract Treatment-resistant schizophrenia (TRS) will affect about one in three patients with
schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be …

Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review

E Wagner, S Siafis, P Fernando, P Falkai… - Translational …, 2021 - nature.com
A recent increase in the literature regarding the evidence base for clozapine has made it
increasingly difficult for clinicians to judge “best evidence” for clozapine use. As such, we …

[HTML][HTML] Schizophrenia: The new etiological synthesis

MJ Rantala, S Luoto, JI Borráz-León, I Krams - … & Biobehavioral Reviews, 2022 - Elsevier
Schizophrenia has been an evolutionary paradox: it has high heritability, but it is associated
with decreased reproductive success. The causal genetic variants underlying schizophrenia …

[HTML][HTML] Treatment-resistant schizophrenia: definition, predictors, and therapy options

CU Correll, OD Howes - The Journal of clinical psychiatry, 2021 - psychiatrist.com
Treatment-resistant schizophrenia (TRS) represents a major clinical challenge. The broad
definition of TRS requires nonresponse to at least 2 sequential antipsychotic trials of …

EPA guidance on treatment of negative symptoms in schizophrenia

S Galderisi, S Kaiser, I Bitter, M Nordentoft… - European …, 2021 - cambridge.org
Negative symptoms of schizophrenia remain a major therapeutic challenge. The progress in
the conceptualization and assessment is not yet fully reflected by treatment research …

Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia

SM Paul, SE Yohn, M Popiolek… - American Journal of …, 2022 - Am Psychiatric Assoc
Schizophrenia remains a challenging disease to treat effectively with current antipsychotic
medications due to their limited efficacy across the entire spectrum of core symptoms as well …

Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies

N Dedic, H Dworak, C Zeni, G Rutigliano… - International Journal of …, 2021 - mdpi.com
Trace amine-associated receptor 1 (TAAR1) has emerged as a promising therapeutic target
for neuropsychiatric disorders due to its ability to modulate monoaminergic and …

New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics

MC Lobo, TS Whitehurst, SJ Kaar, OD Howes - … & Biobehavioral Reviews, 2022 - Elsevier
Schizophrenia is associated with substantial unmet needs, highlighting the necessity for
new treatments. This narrative review compares the pharmacology, clinical trial data and …